Burden of cancer attributable to exogenous hormone use in Japan in 2015

DOI Web Site Web Site 被引用文献2件 参考文献18件 オープンアクセス
  • Hirabayashi Mayo
    Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
  • Nagata Chisato
    Department of Epidemiology and Preventive Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Abe Sarah Krull
    Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
  • Sawada Norie
    Division of Cohort Research, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
  • Saito Eiko
    Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
  • Hori Megumi
    Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
  • Katanoda Kota
    Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
  • Matsuda Tomohiro
    National Cancer Registry Section Center for Cancer Registries Center for Cancer Control and Information Services/Office of International Affairs, Strategic Planning Bureau National Cancer Center, Japan, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
  • Inoue Manami
    Division of Prevention, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. Division of Cohort Research, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
  • the Cancer PAF Japan Collaborators

この論文をさがす

説明

<p>Exogenous female hormone use has not been as popular in Japan as in western populations. Here, we estimated the population-attributable fraction (PAF) of cancers in Japan in 2015 attributed to exogenous female hormone use. We used the most recent prevalence data for oral contraceptives (OC) and hormone replacement therapy (HRT), available from a large-scale population-based cohort study started in 2011-2016. For the purpose of this study, optimal usage of exogenous hormones was considered to be none. PAF was calculated for each age group using a standard formula. Overall, a negligible fraction, 0.4% of cancer incidence and 0.2% of cancer mortality in Japanese women was attributable to exogenous hormone use (OC use and HRT), and 0.2% of cancer incidence and 0.1% of cancer mortality overall when both sexes combined. The relatively low prevalence of exogenous hormone use in Japan compared to Western countries may explain the low fraction of cancer attributable to exogenous hormones among Japanese women. </p>

収録刊行物

  • GHM Open

    GHM Open 1 (2), 97-101, 2021-12-31

    国立研究開発法人 国立国際医療研究センター

被引用文献 (2)*注記

もっと見る

参考文献 (18)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ